Issue 5 - Feb 2, 2018
  • Like it or not, CMS policy aims to change everything in Next generation sequencing

    A policy now in the works at the Centers for Medicare and Medicaid Services will define settings where Medicare will pay for next generation sequencing.

    The health care funding agency will use FDA approval of NGS tests to determine whether these tests are covered outright, receive “coverage with evidence development,” or are denied coverage altogether.

  • Dear CMS, Here’s what I think about your NGS policy… Agency draft memo garners 315 comments

    The range of opinions reflected in the 315 comments CMS received on its proposal for Medicare payment for Next Generation Sequencing reflects the extent of controversy over the test.

  • Conversation with the Cancer Letter

    Miller: “Doctors and patients have confidence in knowing that a test has gone through FDA”

    Concurrent FDA approval and the establishment of Medicare coverage will propel Next generation sequencing squarely into the mainstream of oncology practice, said Vincent Miller, chief medical officer of Foundation Medicine Inc.

  • In Brief

    • Mays Family Foundation makes legacy gift of $30 million to UT Health San Antonio Cancer Center
    • Sylvester Comprehensive Cancer Center to build proton therapy program
    • Syapse partners with Seoul National University Hospital and Megazone
    • Buchholz named medical director at Scripps MD Anderson Cancer Center
    • Kati Stoermer named executive director NRG Oncology
    • James Wade joins Vibrent Health as chief medical informatics officer
    • SU2C announces $11 million multi-disciplinary research program
    • Chen, Bild, Kahn, Heisterkamp join City of Hope
    • New building expands inpatient care at Siteman Cancer Center
    • CancerCare raises nearly $665,000 to support patients affected by hurricanes
    • Cancer Support Community adds Digital Nonprofit MyLifeLine to its network
  • Funding Opportunities

    AACR announces AACR-J&J lung cancer innovation science grants

    The American Association for Cancer Research has launched the AACR-Johnson & Johnson Lung Cancer Innovation Science Grants.

    A total of $4.5 million will be made available in research funding. Three multi-institutional research teams that seek novel approaches to the prevention, interception, and cure of lung cancer will each be awarded up to $1.5 million over three years.

  • TCCL Logo

  • Trials and Tribulations

    Re: Drug Pricing My unsolicited advice to HHS Secretary Alex Azar

    Dear Mr. Azar:

    I am the leader of CancerCare, a national organization that provides free, professional support services to anyone affected by cancer. I’m writing this letter to offer some perspective regarding the plight of nearly 16 million U.S. cancer survivors, the many more who are family and care providers, and all of those who will be diagnosed in the coming years.

  • Clinical Roundup

    Trial shows durable remissions with Kymriah in children, young adults with r/r ALL

    Novartis has announced updated results from the pivotal ELIANA clinical trial of Kymriah (tisagenlecleucel), formerly CTL019, in relapsed or refractory (pediatric and young adult patients with B-cell acute lymphoblastic leukemia have been published in The New England Journal of Medicine. New data include longer-term follow-up and efficacy in 75 infused patients, analysis of expansion and persistence of Kymriah, and longer-term safety.

  • Drugs and Targets

    • FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS
    • Amgen receives CHMP positive opinion to add updated survival data to Kyprolis label
    • Syndax announces immuno-oncology collaboration with AstraZeneca
Issue 4 - Jan 26, 2018
Issue 3 - Jan 19, 2018
  • Guest Editorial

    A unique drug for each patient: a paradigm shift in cancer therapy

    The recent FDA approvals of a cell/gene therapy for patients with advanced B cell malignancies provide a glimpse into a paradigm shift in the treatment of hematologic and solid cancers, the creation of a new drug unique to each cancer patient.

  • News Analysis

    As government shutdown looms, don’t lose sight of bigger battle over appropriations, sequestration

    As the rancor in Washington continues to escalate from bickering to a war on many fronts, the deadline approaches for the end of a continuing resolution that keeps the federal government open until Jan. 19.

  • In Brief

    • Allison, Bax, Doudna and Chang receive NAS prizes
    • Kathy Albain receives first Huizenga Family Endowed Chair at Loyola University Chicago
    • ACS CAN: Cancer patients should be exempt from possible Medicaid work requirements
    • ACCC’s 2017 survey: cost of treatment is top threat to cancer program growth
  • TCCL Logo

  • Clinical Roundup

    • Blood test for eight cancer types provides framework for early detection
    • Study shows screening population for select genes is a cost-effective solution
    • Polygenic hazard score predicts when men develop prostate cancer
    • Exelixis and Ipsen announce phase III trial results of Cabozantinib in advanced hepatocellular carcinoma
  • Drugs and Targets

    • Foundation Medicine and Pfizer form partnership to develop companion diagnostics
    • FDA approves addition of overall survival data to Kyprolis
    • Novartis granted FDA Priority Review for Kymriah for adults with r/r DLBCL
  • CTEP Protocols

    NCI CTEP-Approved Trials for January

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

    For further information, contact the principal investigator listed.